AptaBio Therapeutics Inc. Overview
AptaBio Therapeutics is a small-cap, clinical-stage Korean drug developer built on two proprietary discovery platforms. The first is a NADPH oxidase (NOX) inhibition platform for modulating oxidative stress. The second is an aptamer–drug conjugate (Apta-DC) platform that couples a G-quadruplex DNA aptamer with cytotoxic nucleoside drugs. The company's value is concentrated in isuzinaxib (APX-115), an oral pan-NOX inhibitor. Isuzinaxib is in Phase 2 for contrast-induced acute kidney injury (CI-AKI), where no therapy is approved, and in Phase 2b for diabetic kidney disease (DKD). Behind it sit APX-343A, a NOX-based modulator of cancer-associated fibroblasts in Phase 1 with Merck-supplied Keytruda; ABF-101, an oral wet-AMD candidate in US Phase 1; and Apta-16 for relapsed/refractory AML. Revenue (KRW 3.7 bn in FY2025) comes almost entirely from a health-functional-food ODM business added in late 2023 to meet KOSDAQ minimum-revenue rules. The equity story depends on converting the October 2026 CI-AKI readout into a licensing deal before cash runs short.
What the company does. AptaBio discovers and develops first-in-class small-molecule and conjugate drugs for intractable diseases. Its pipeline uses two platforms. The NOX inhibitor platform targets NOX isozymes, the enzyme family that generates reactive oxygen species (ROS); the lead compound isuzinaxib inhibits all seven NOX isoforms. The Apta-DC platform modifies the G-quadruplex aptamer AS1411 by substituting an anti-metabolite (gemcitabine or azacitidine) at a specific nucleotide position, so the aptamer delivers the payload to cancer cells (Source: Samsung Securities initiation, 26 Dec 2019; Hankyung, 27 Apr 2026). Since 2024 the company has presented a third technology theme, cancer-associated fibroblast (CAF) modulation. In practice this is a NOX-platform application: APX-343A blocks CAF–M2 macrophage crosstalk in the tumour microenvironment (Source: Edaily, Nov 2025; company IR 2024).
Company's own description. In its 2024 IR deck the company describes itself as a platform-based developer of first-in-class innovative drugs. It lists three focus areas (diabetic complications, intractable cancers, cancer immunotherapy) and three platforms (oxidative stress modulation, aptamer–drug conjugates, CAF modulation), under the mission phrase "Make Life Better" (Source: AptaBio IR 2024, July 2024). Its BIO International Convention exhibitor profile names Apta-DC and NOX inhibitors as its two proprietary platforms (Source: BIO 2026 exhibitor listing).
Business model and revenue model. The model is out-licensing, not commercialisation. AptaBio aims to take assets through clinical proof-of-concept (Phase 1/2) and then license them to larger pharma for upfront payments, milestones and royalties. Historical licensing income has been small. Kiwoom (2021) and IB Tomato (2023) data show revenue of KRW 1.5 bn in FY2018 and KRW 1.0 bn in FY2019, mainly licence-related, which then fell to near zero by FY2022. To avoid KOSDAQ "administrative issue" designation (consolidated revenue below KRW 3 bn after the technology-listing grace period), the company created a New Business Division in November 2023. The division covers gene-delivery reagents, health-functional-food (HFF) ODM, and pet-care product distribution (Source: Kormedi, Dec 2023; IB Tomato, Jul 2024). By 2Q 2026, HFF ODM made up 100% of quarterly revenue (Source: Butler segment data).
Value-chain position. Upstream discovery and early/mid-stage clinical development. Manufacturing, late-stage trials and commercialisation are expected to sit with licensees. CROs run the trials (for example, Covance on the 2021 US COVID-19 Phase 2 plan, and a Japanese non-clinical CRO for ABF-101 genotoxicity work).
Customer types and end-markets. Prospective pharma licensees in nephrology, interventional cardiology/radiology (CI-AKI), ophthalmology (wet AMD, diabetic retinopathy), hepatology (MASH) and oncology (solid tumours, AML). Current revenue customers are Korean HFF brand owners and online retail channels (ODM), and earlier, pet owners via distribution.
Independent characterisation. AptaBio is a pre-revenue platform biotech with a low-margin consumer-health side business that exists mainly to preserve its listing. Its scientific differentiation is real but narrow. The company says isuzinaxib is one of only two clinical-stage NOX inhibitors globally, the other being Calliditas' setanaxib (Source: Money Today/Daum, Aug 2024). Its financial position is fragile: cumulative operating losses for FY2021–FY2025 were about KRW 74 bn. Funding has relied on convertible instruments, and in 2026 cash was supplemented by selling down an affiliate stake. The October 2026 CI-AKI Phase 2 readout is the defining event for the company.
Strategy
Stated strategy (themes from IR 2024 and 2026 management statements).
-
Platform-driven first-in-class development in areas of high unmet need: diabetic complications, intractable cancers, and CAF-related immuno-oncology (IR 2024).
-
Out-licensing at proof-of-concept. At IPO the company targeted five licensing deals by 2020 (Biospectator, 2019). In 2026 it is pursuing an isuzinaxib licence after topline data, possibly packaging CI-AKI with DKD (Dailian, Jul 2026; Dailypharm, Oct 2026).
-
Platform-licensing business model. Management stated it wants to build a model where the platform itself is licensed, on the back of 2026 clinical progress (Dealsite, Jan 2026).
-
Revenue base for listing compliance through the New Business Division (HFF ODM, pet care, gene delivery), with a target of KRW 3–4 bn per year (Kormedi, Dec 2023).
Initiatives in the last 24 months:
ESG commitments: None published. Cost programmes: None announced. Medium-term financial targets/guidance: None published. Earlier IPO-era revenue forecasts were missed by 96–100% (Dealsite, Feb 2024).
Products & Services
5A. NOX (oxidative-stress modulation) platform
Isuzinaxib (APX-115) — contrast-induced acute kidney injury (CI-AKI).
Description: Oral pan-NOX inhibitor covering all seven NOX isoforms. It is dosed once daily from two days before contrast exposure to three days after, for up to five days (Source: Hankyung, 27 Apr 2026).
Preclinical evidence: In CI-AKI animal models, BUN and creatinine improved, kidney-injury markers fell, tubular injury and inflammation decreased, and NOX1/2/4 expression went down (Source: Biospectator, May 2022).
Clinical: Randomised, double-blind, placebo-controlled Phase 2 in PCI patients at 14 large hospitals in Korea and the US (NCT05758896). Enrolment target was cut from 200 to 160 by protocol amendment (MFDS March 2026; FDA April 2026); 159 patients were dosed, with dosing completed April 2026 and follow-up in July 2026. The original registry design called for ~280 patients randomised 1:1 to 400 mg or placebo (ClinicalTrials.gov). A sentinel cohort showed no unexpected adverse events in CKD patients. In that cohort, 26.7% of patients had creatinine rise above 1.2 mg/dL within 48 hours of PCI, and this predicted lower eGFR at 12 weeks (p = 0.025) (ASN 2025 LBCT poster, per Medical Today, Nov 2025).
Topline (14–15 Oct 2026): The primary endpoint was safety and was met. Adverse events, physical exams, ECG, vitals and labs showed no clinically meaningful differences versus placebo, including in patients with eGFR at or below 45. Key secondary efficacy endpoints are not yet disclosed and will be presented orally at ASN Kidney Week 2026 in Denver on 23 October 2026. The final clinical study report is expected by 1H 2027 (Source: Dailypharm, Medipana, Pharmnews, Vegan News, 15 Oct 2026).
Target customer: Licensee targeting interventional cardiology and radiology. The company cites CI-AKI incidence of ~10% of PCI patients, rising to ~33% in pre-existing kidney disease, and notes no approved preventive drug beyond IV hydration (Source: Hankyung, Apr 2026).
Pricing: Not applicable (development stage).
Isuzinaxib (APX-115) — diabetic kidney disease (DKD).
Phase 2a (Europe, NCT04534439): 140 type-2 DKD patients at 16 hospitals in Bulgaria, Czechia, Hungary and Serbia; 400 mg (n = 68) vs placebo (n = 72) once daily for 12 weeks. The primary endpoint (UACR change vs placebo) was not statistically significant. UACR fell more than 20% from baseline in the drug arm (p < 0.05) vs under 3% in the placebo arm. In patients with eGFR below 45, the drug arm showed more than 50% UACR reduction vs placebo (p < 0.05). In a PK/PD-defined compliant subgroup (44 of 68 patients), UACR reduction exceeded 30% vs placebo. Adverse-event rates were under 5% in both arms (Source: Biospectator, 29 Jul 2022).
Phase 2b (PROMISS-DKD, NCT06962098): Dose-ranging, quadruple-blind, placebo-controlled, recruiting in Korea. Enrolment requires UACR of 200–3,000 mg/g on stable ACEi/ARB (ClinicalTrials.gov; Dailian, Jul 2026).
Strategy: The company has said it may license CI-AKI and DKD together as one package (Dailian, Jul 2026; Dailypharm, Oct 2026).
Isuzinaxib (APX-115) — COVID-19 (discontinued in practice). FDA cleared a US Phase 2 in early 2021 (80 patients, Covance). The company later said recruiting hospitalised patients was no longer feasible after vaccination spread (Source: Pharmaceutical Technology, 2021; Dealsite, Feb 2024).
ABF-101 — wet age-related macular degeneration (oral).
Description: Oral NOX-platform candidate for AMD.
Clinical: US Phase 1 (NCT07330674). Part A single ascending dose and Part B multiple ascending dose in healthy volunteers; Part C open-label in AMD patients. IND filed July 2025 and cleared 23 October 2025 (IND 176088). Placed on clinical hold in February 2026 over genotoxicity-data integrity at a Japanese CRO after a PMDA inspection; hold lifted 16 June 2026 after supplementary data and repeat testing (Source: Digital Today, Oct 2025; Biospectator, Feb 2026; Edaily, Jun 2026).
Differentiation: Oral dosing as an alternative to intravitreal anti-VEGF injections.
ABF-103 — wet AMD (eye drop). Topical candidate; clinical entry was guided for end-2024 (Daum, Aug 2024).
APX-1004F / SJP1804 — wet AMD (eye drop). Licensed to Samjin Pharm in 2018. Samjin obtained Korean Phase 1 approval in November 2021 (Financial News, Jul 2022).
APX-1004 — diabetic retinopathy. The 1H 2025 report planned Phase 2 entry within 2025 (IB Tomato, Nov 2025).
APX-311 — MASH (formerly NASH). European Phase 1 completed before the 2019 IPO (Medigate, Apr 2019). Phase 2 entry planned within 2025 per the 1H 2025 report (IB Tomato, Nov 2025).
APX-5278 — arteriosclerosis. Preclinical (IR 2024).
APX-New1 — Parkinson's disease. Preclinical (IR 2024).
5B. CAF modulation (NOX-based immuno-oncology)
APX-343A — advanced solid tumours.
Mechanism: Selective NOX inhibitor that blocks CAF–M2 macrophage interaction, relieves tumour-microenvironment immunosuppression and promotes immune-cell infiltration (Edaily, Nov 2025).
Clinical: Phase 1 (NCT07123415). Open-label dose escalation, oral twice daily. Part A is monotherapy; Part B combines with pembrolizumab. ~110 patients at 3 Korean sites; first dosing 18 November 2025. Monotherapy PK/PD data were presented at ASCO 2026; the company says target exposure was reached (ClinicalTrials.gov; Edaily, Jul 2026).
Partnership: MSD supplies Keytruda under an August 2024 clinical trial collaboration and supply agreement. AptaBio is sponsor. Per the company, it was one of only two preclinical-stage combination agreements among MSD's 11 Korean Keytruda collaborations (Money Today, Aug 2024).
Positioning: Management presents APX-343A as a potential successor to Lenvima as a Keytruda combination partner, acting through CAFs rather than VEGF (Edaily interview, Jul 2026).
5C. Apta-DC (aptamer–drug conjugate) platform
Apta-16 — relapsed/refractory AML.
Description: G-quadruplex aptamer–drug conjugate. The company says the G-quadruplex fold gives stability without the heavy chemical modification used in older aptamer drugs (Edaily, Jul 2026).
History: Licensed to Samjin Pharm (as SJP1604) in 2016; Korean Phase 1 entered in 2020 (Medigate, Nov 2020).
Recent data: AACR 2025 (cytarabine-resistant cell lines); AACR 2026 (venetoclax-resistant animal model, including MCL-1 modulation); Phase 1 trial-design poster accepted for ESMO 2026, Madrid, October 2026 (Edaily, 20 Jul 2026).
Note: Recent disclosures present Apta-16 as an AptaBio-led asset.
Apta-12 — pancreatic cancer. Licensed to Hope Biosciences (US) in January 2017. As of April 2019 preclinical work had not started (Dealsite, Apr 2019).
5D. Commercial (non-pharma) products
| Product / service | Category | Target customer | Notes |
|---|---|---|---|
| HFF ODM services | Contract manufacturing | Supplement brand owners | 100% of 2Q 2026 revenue (Butler) |
| Imported pet health supplements | Distribution | Korean pet owners | Pet company merged June 2025; planned own-brand supplements using pipeline active ingredients (Kormedi, Dec 2023) |
| Lipofector-Q / -EXT / -2000 / -EZ / -pMAX | Transfection reagents for DNA/RNA into eukaryotic cells | Research labs | Listed in third-party profile (Simply Wall St); revenue not disclosed |
Financial Narrative
Basis: Consolidated K-IFRS, FY ending 31 December, KRW. Primary source: DART annual reports as compiled by ETF Shopping and Butler (accessed October 2026). Revenue to two decimals is derived from reported revenue and operating margin.
6B. Margins
Revenue CAGR FY2021–FY2025: ~101% per year (KRW 0.22 bn → KRW 3.69 bn), which is mathematically correct but distorted by a near-zero base and a change in business mix. Earlier reference: Kiwoom (2021) gives FY2017–FY2020 revenue of KRW 0.3/1.5/1.0/0.3 bn and EBITDA of -2.0/-3.4/-7.1/-5.8 bn. EBITDA for FY2021–FY2025 is not publicly disclosed; Kiwoom's FY2020 figures suggest D&A of only ~KRW 0.3 bn, so EBITDA is likely close to operating income.
Commentary. Operating losses grew from KRW 9.5 bn (FY2022) to KRW 18.9 bn (FY2024) as CI-AKI and DKD trials ran in parallel. They then eased to KRW 15.8 bn in FY2025, helped by a better gross margin and, per 1H 2025 data, lower R&D spend (1H 2025 operating loss KRW 6.8 bn; IB Tomato, Nov 2025). Net loss of KRW 29.4 bn in FY2024 was far above the KRW 18.9 bn operating loss, implying ~KRW 10.5 bn of net non-operating losses. The 2023 guidance gap is stark: IPO-era projections called for revenue of KRW 27.7 bn (2019), 76.7 bn (2020) and 66.9 bn (2021 and 2022), against actuals near zero (Dealsite, Feb 2024).
6C. Balance sheet
Sources: cash+ST for FY2021–FY2022 from IB Tomato (Aug 2023); net cash change from ETF Shopping (DART).
Derived equity estimate (not reported directly). Market cap divided by quoted P/B gives implied book equity of ~KRW 42–47 bn. FY2025 ROE of -34.6% and ROA of -27.2% (ETF Shopping) imply average equity of ~KRW 47 bn and average assets of ~KRW 60 bn, so liabilities were roughly a fifth of assets on average in FY2025. These are analyst derivations, not filed figures.
Convertible financing register:
Derived: at KRW 9,565, 757,440 convertible shares imply ~KRW 7.2 bn of CB face value outstanding at end-December 2025.
6D. Cash flow
FY2023's +KRW 23.0 bn cash increase reflects the August 2023 KRW 50 bn raise net of operating burn and investments. No company buybacks were identified. Executives bought shares personally in 2023, and the employee stock ownership association bought ~KRW 0.4 bn (Dealsite, May 2023).
6E. Ratios
Source: ETF Shopping (FY2025). Leverage and coverage ratios are not meaningful with negative EBITDA. Asset turnover using derived average assets would be about 0.06x in FY2025 (derived).
Trend commentary. (1) Revenue: the inflection in FY2024 is structural (new consumer business), not organic pharma revenue. (2) Profitability: gross margin improved to 36% in FY2025, but gross profit (KRW 1.3 bn) covers less than 10% of operating losses. Payroll (KRW 3.17 bn) exceeded separate revenue (KRW 3.15 bn) in FY2025 (ETF Shopping). (3) Liquidity: the cash runway has been short repeatedly. IB Tomato estimated under two years of runway at mid-2025, before any new trial starts or CB puts. In 2026 the company met CB puts by monetising part of its FMW holding. (4) Dilution: shares outstanding rose from 11.10 million (2020) to 28.09 million (2025), up 153%, driven by the 2021 bonus issue and 2023–2024 conversions (ETF Shopping).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line | Content | Products/services |
|---|---|---|
New drug R&D (core) | NOX platform, Apta-DC platform, CAF modulation | Isuzinaxib (APX-115), APX-343A, ABF-101, ABF-103, APX-311, APX-1004/1004F, APX-5278, APX-New1, Apta-16, Apta-12 |
Health-functional-food ODM | Contract development and manufacture of supplements for brand owners | Product list not disclosed |
Pet-care distribution | Import and distribution of pet health supplements (Europe/North America brands); pet-products company merged in June 2025 | Product list not disclosed |
Gene-delivery reagents | Transfection reagents | Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, Lipofector-pMAX |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 0.32 | 3.37 | 3.69 |
Revenue YoY growth (%) | 569.8 | 937.8 | 10.0 |
HFF ODM by Period
| Period | HFF ODM (KRW Bn) | Pet care (KRW Bn) | Total (KRW Bn) | HFF share (%) | Source |
|---|---|---|---|---|---|
Nov–Dec 2023 (new division, ~2 months) | — | — | 0.3 | — | IB Tomato, Jul 2024 |
1Q 2024 | 0.45 | 0.17 | 0.64 | 70.67 | IB Tomato, Jul 2024 |
1H 2024 | 1.0 | 0.7 | 1.8 | — | Daum/Bizwatch, Aug 2024 |
2Q 2026 | — | — | — | 100 | Butler |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 0.22 | 0.05 | 0.32 | 3.37 | 3.69 |
Cost of revenue (KRW Bn) | — | — | 0.2 | 3.1 | 2.4 |
Gross profit (KRW Bn) | — | — | 0.1 | 0.3 | 1.3 |
Operating income (KRW Bn) | -11.4 | -9.5 | -16.4 | -18.9 | -15.8 |
Net income (KRW Bn) | -10.7 | -10.6 | -12.1 | -29.4 | -16.3 |
EPS basic (KRW) | -712 | -474 | -532 | -1,248 | -607 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | 24.2 | 8.5 | 36.0 |
Operating margin (%) | -5,081.9 | -19,661.2 | -5,055.6 | -561.0 | -428.4 |
Net margin (%) | -4,778.8 | -21,849.3 | -3,724.2 | -874.1 | -442.0 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash + short-term financial products (KRW Bn) | 14.7 | 16.9 | — | — | — |
Net change in cash and cash equivalents (KRW Bn) | -8.1 | -4.6 | 23.0 | 0.5 | -9.5 |
Cash Flow History
| Date | Cash + ST financial products (KRW Bn) | Source |
|---|---|---|
31 Dec 2019 | 36.1 | IB Tomato, Aug 2023 |
31 Dec 2020 | 30.1 | IB Tomato, Aug 2023 |
30 Jun 2023 | 10.1 | IB Tomato, Aug 2023 |
31 Mar 2024 | 45.1 | IB Tomato, Jul 2024 |
30 Jun 2025 | 22.6 (21.6 cash + 1.0 ST) | IB Tomato, Nov 2025 |
2Q 2026 | Bizwatch reports cash could have fallen to the KRW 1 bn range without the ~KRW 9.4 bn FMW stake sale | Bizwatch, Aug 2026 |
Capital Instruments
| Instrument | Date | Amount (KRW Bn) | Terms / events | Source |
|---|---|---|---|---|
Third-party placement (convertible preferred, CPS) | Aug 2023 | 11.1 | Converted in part in Jul 2024 | IB Tomato; News Tomato |
1st-series private CB | 24 Aug 2023 | 38.9 | — | DART notice; Dealsite |
Conversions (CPS + CB) | 27–28 Jun 2024 | 18.4 | 10.90% of the ~22.3 million shares then outstanding | News Tomato, Jul 2024 |
Put-option redemptions | 2026 | ~4.9 | Funded partly by FMW stake sale | Bizwatch, Aug 2026 |
Pre-maturity CB acquisition | 24 Aug 2026 | — | DART filing type: CB acquired before maturity | Butler (filings list) |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%)
| Metric | FY2025 |
|---|---|
ROE (%) | -34.6 |
ROA (%) | -27.2 |
Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consolidated revenue (KRW Bn) | 0.32 | 3.37 | 3.69 |
Parent-only (separate, Korea) revenue (KRW Bn) | — | — | 3.15 |
Implied subsidiary contribution (KRW Bn) | — | — | 0.54 |
Share Price & Returns
| Reference point | Price (KRW) | Notes / source |
|---|---|---|
IPO price (Jun 2019) | 30,000 | Pre-bonus issue; ~15,000 adjusted for the 2021 1:1 bonus issue (Biospectator) |
21 Jul 2021 | 68,400 | Pre-bonus; market cap KRW 758.9 bn (Kiwoom) |
26 Aug 2021 | 49,900 | Pre-bonus; market cap KRW 553.1 bn (Aju News) |
24 Aug 2026 | 6,180 | Below the KRW 7,240 CB conversion reference cited by Bizwatch |
14 Oct 2026 (close) | 6,650 | Market cap KRW 186.8 bn (ETF Shopping) |
52-week high / low | 10,420 / 4,000 | ETF Shopping, as of 14 Oct 2026 |
Period return to 14 Oct 2026 | Return (%) | Source |
1 month | 3.9 | ETF Shopping |
6 months | -8.1 | ETF Shopping |
1 year | -17.2 | ETF Shopping |
5 years | About -80 (derived) | Bonus-adjusted mid-2021 levels of ~KRW 25,000–34,000 vs KRW 6,650; approximate |
Valuation Multiples
| Multiple | AptaBio | Notes |
|---|---|---|
P/B | 3.96–4.39 | ETF Shopping (3.96); Butler (4.39); different book-value dates |
EV/Sales | ~50x (approximate) | — |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | No active consensus; StockHub shows 0 covering reports (Jul 2026). Historical "Not Rated" note from Kiwoom (Jul 2021); Samsung Securities initiation (Dec 2019) |
Dividend history and policy | No dividends paid since founding; 0% yield |
Buyback authorisations | None identified |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Metric | FY2021 |
Dividends per share (KRW) | 0 |
Largest shareholder group stake (%) | 33.62 |
Analyst Conclusions
Management guidance. No financial guidance is published. Operational guidance: present CI-AKI secondary efficacy results orally at ASN Kidney Week 2026 (Denver, 23 October 2026); receive the final CSR by 1H 2027; pursue licensing of isuzinaxib for CI-AKI alone or packaged with DKD; resume and advance ABF-101 US Phase 1; open the Keytruda combination arm of APX-343A; present Apta-16 Phase 1 design at ESMO 2026 (Dailypharm; Edaily; Money Today).
Consensus growth expectations. None; there is no active sell-side coverage.
Bull case
-
First-in-class CI-AKI asset with a clean safety profile. If efficacy endpoints at ASN show a clinically meaningful reduction in kidney injury, isuzinaxib would be a Phase 2-validated asset in a market with no approved drug, and it already meets the primary safety endpoint.
-
Several shots on goal from one platform. CI-AKI, DKD, oral AMD and IO combination programmes all draw on NOX chemistry, so one licence could validate the rest of the portfolio.
-
Low valuation relative to option value. At ~KRW 187 bn market cap, a single upfront payment in the tens of billions of won plus milestones could re-rate the stock, given fixed costs of ~KRW 16 bn per year.
Bear case
-
Efficacy may not follow safety. The primary endpoint was safety; the trial was downsized to 159–160 patients, and the earlier DKD Phase 2a missed its primary efficacy endpoint. Ambiguous secondary data would weaken licensing leverage.
-
Financing pressure. Cash runway was under two years at mid-2025, and the 2026 CB puts were met only by selling an affiliate stake. A new dilutive raise seems likely without a licence.
-
Track record of missed targets. Revenue projections were missed by 96–100%, the 2020 licensing target was missed, and the revenue base is a low-margin ODM business kept largely to preserve the listing.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| 23 Oct 2026 | CI-AKI Phase 2 efficacy data, ASN Kidney Week 2026 oral session |
| Oct 2026 | Apta-16 Phase 1 design poster, ESMO 2026 (Madrid) |
| 4Q 2026 – 1H 2027 | Isuzinaxib licence (CI-AKI and/or DKD package) |
| By 1H 2027 | Final CI-AKI CSR |
| 2026–2027 | APX-343A + Keytruda combination cohort initiation and first data |
| 2026–2027 | ABF-101 Phase 1 SAD/MAD progress and AMD patient cohort |
| 2,027 | DKD Phase 2b (PROMISS-DKD) enrolment and readout timing |
| Mar 2027 | FY2026 annual report: revenue must stay at or above KRW 3 bn; cash balance; any going-concern language |
| Ongoing | New CB/rights issues, conversion-price resets, FMW IPO and stake monetisation |
Concluding analyst verdict
AptaBio is a single-catalyst, balance-sheet-constrained platform biotech approaching its most important data event since its 2019 IPO. The science is credible within its niche. Isuzinaxib has now gone through two Phase 2 programmes without safety concerns, has been selected three times for prominent ASN slots, and targets a CI-AKI indication with no approved therapy and a clear clinical problem in interventional cardiology. The NOX platform's spread across kidney, eye, liver and oncology indications gives a licensee more than one asset to evaluate, and the MSD supply arrangement adds some outside validation to the oncology work.
The financial and execution record is weaker. Operating losses have run at KRW 9.5–18.9 bn per year against negligible drug revenue. The consumer-health revenue line exists largely to satisfy KOSDAQ rules. IPO-era forecasts were missed almost entirely. Liquidity in 2026 depended on selling part of the FMW stake to meet bondholder puts. Shares outstanding have more than doubled since 2020, and the founders' control stake has fallen to 27%. The topline disclosed on 14–15 October 2026 confirms safety only; the efficacy results that matter for licensing are still to come.
On balance, the investment case is binary and should be sized as such. If the 23 October ASN presentation shows a consistent, clinically meaningful reduction in contrast-induced kidney injury, especially in high-risk CKD patients, AptaBio has a credible route to its first material licence, which could fund the DKD and AMD programmes and justify a re-rating from ~50x trailing sales. If the efficacy signal is weak or limited to subgroups, the company will likely need another dilutive raise within a year, and the market may value it mainly on remaining cash and early-stage options. The key items to monitor are the efficacy effect size, any partner announcement before the CSR, and the capital-raising plan in the FY2026 annual report.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation |
|---|---|---|---|---|
Lee Soo-jin (이수진) | Co-founder, CEO (Representative Director) | Since 2009 founding | Drug-discovery career at JW Pharmaceutical (중외제약) central research institute, including head of new-drug research; overseas joint-research experience (Biospectator, Apr 2019; Medigate, Apr 2019) | Not individually disclosed (Korean rules require individual disclosure only above KRW 500 m) |
Moon Sung-hwan (문성환) | Co-founder, President & CTO | Since 2009 founding | C&C Research Laboratories; Hanmi Pharm; VP and head of research at Beijing Hanmi; global BD and commercialisation (Biospectator, Apr 2019) | Not individually disclosed |
Shin Hye-sung (신혜성) | Research Fellow (연구위원); co-author on APX-343A ASCO 2026 abstract | — | Represented the company at JPM 2026 (Dealsite, Jan 2026) | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Relationship | Stake (%) |
|---|---|---|
Lee Soo-jin | Largest shareholder (self) | 17.42 |
Moon Sung-hwan | Executive (related party) | 8.88 |
Moon Ho-sang | Spouse (related party) | 0.85 |
Moon Ji-kwon | Child (related party) | 0.07 |
Largest shareholder group total | — | 27.22 |
National Pension Service | As of end-2023 | 0.05 |
Minority shareholders (24,244 holders) | — | 58.01 |
Metric | FY2021 | FY2022 |
Largest shareholder group stake (%) | 33.62 | 33.38 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor / product | Relative positioning vs AptaBio |
|---|---|---|
NOX inhibition (platform) | Calliditas Therapeutics' setanaxib (Calliditas acquired by Asahi Kasei, 2024) | Only other clinical-stage NOX inhibitor per AptaBio; better-funded owner; different indications (PBC, other fibrotic diseases) |
CI-AKI | No approved drug; standard of care is IV hydration and limiting contrast volume | AptaBio is among few with a CI-AKI-specific Phase 2; advantage of being early, but no validated regulatory path |
AKI (adjacent settings) | Renibus Therapeutics (RBT-1, cardiac-surgery AKI); Guard Therapeutics (RMC-035, cardiac-surgery AKI); AM-Pharma (ilofotase alfa, sepsis-associated AKI) | Further along or larger trials in other AKI settings; set the bar for AKI trial design |
DKD | Bayer (Kerendia/finerenone); AstraZeneca (Farxiga) and Boehringer/Lilly (Jardiance) SGLT2 inhibitors; Novo Nordisk (Ozempic, kidney-outcomes label); Boehringer Ingelheim (vicadrostat, aldosterone synthase inhibitor); Mineralys (lorundrostat) | Crowded, outcome-validated standard of care; isuzinaxib would be an add-on and needs hard renal outcomes to compete |
Wet AMD | Regeneron/Bayer (Eylea, Eylea HD); Roche (Vabysmo); Novartis (Beovu); Ocular Therapeutix and EyePoint sustained-release TKIs | Oral delivery is a differentiator but early (Phase 1); incumbents dominate |
Immuno-oncology combinations | Eisai (Lenvima, with Keytruda); numerous PD-1 combination programmes | APX-343A is early (Phase 1); MSD supply deal is not a co-development commitment |
R/R AML | AbbVie (Venclexta); Astellas (Xospata); Servier (Tibsovo); Syndax (Revuforj); Kura (ziftomenib) | Apta-16 is Phase 1 into a market with multiple targeted agents |
Aptamer–drug conjugates | Aptamer Sciences (Korea); TAGCyx Biotechnologies (Japan, named by CB Insights) | Small, niche modality; peers similarly early-stage |
HFF ODM (revenue business) | Kolmar BNH, Cosmax NBT, Novarex (Korean HFF ODMs) | Sub-scale; no competitive moat |
Peer Comparison FY2025
| Metric | AptaBio (FY2025) | Renibus Therapeutics |
|---|---|---|
Revenue (KRW Bn) | 3.69 | Private |
Revenue growth (%) | 10.0 | Private |
Operating margin (%) | -428.4 | Private |
R&D intensity (%) | — | Private |



